

Commissioner for Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

0 9 OCT 2007

33197 STOUT, UXA, BUYAN & MULLINS LLP 4 Venture, Suite 300 Irvine, CA 92618

In re Application of WALLACE et al

U.S. Application No.: 10/594,825 PCT No.: PCT/US2005/010266

Int. Filing Date: 29 March 2005 Priority Date: 29 March 2004

Attorney Docket No.: UCIVN-061US

METHODS AND COMPOSITIONS FOR

PRE-SYMPTOMATIC AND POST-SYMPTOMATIC DIAGNOSIS OF

ALZHEIMER'S DISEASE . . .

DECISION ON PETITION UNDER 37 CFR 1.137(b)

Applicants' petition to revive under 37 CFR 1.137(b) filed on 18 September 2007 is hereby **GRANTED** as follows:

The basic national fee and petition fee have been paid. Applicants make the required statement pursuant to 37 CFR 1.137(b)(3). A terminal disclaimer is not required. Accordingly, all requirements under 37 CFR 1.137(b) have been satisfied.

A declaration in compliance with 37 CFR 1.497(a) and (b) was not submitted.

This application is being forwarded to the United States Designated/Elected Office for further processing including mailing a Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) (Form PCT/DO/EO/905) indicating that an oath or declaration in compliance with 37 CFR 1.497(a) and (b) and a surcharge fee are required.

Dames Thomson Attorney Advisor

Office of PCT Legal Administration

Tel.: (571) 272-3302